<DOC>
	<DOCNO>NCT01901159</DOCNO>
	<brief_summary>This randomize , open-label , cross-over study assess bioavailability safety RO4995819 healthy volunteer . Volunteers receive two different formulation ( tablet capsule ) study drug feed fasting condition .</brief_summary>
	<brief_title>A Study RO4995819 Assess Bioavailability Safety Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy nonsmoking male female volunteer , 18 65 year age , inclusive . A body mass index ( BMI ) 18 30 kg/m2 , inclusive . Able participate willing give write informed consent comply study restriction . Willing participate clinical trial investigational drug device least 3 month follow follow visit . Male volunteer partner childbearing potential must use two adequate method contraception . Female volunteer either surgically sterile postmenopausal must commit use two adequate method contraception throughout study least 5 month last dosing . History clinically significant gastrointestinal , renal , hepatic , bronchopulmonary , neurological , psychiatric , cardiovascular , endocrinological , hematological allergic disease , metabolic disorder cancer Significant past present disorder central nervous system , psychiatric disorder , behavioral disturbance Diseases medical condition capable alter absorption , metabolism elimination drug Any condition disease detect medical interview / physical examination would render volunteer unsuitable study , place volunteer undue risk interfere ability volunteer complete study opinion Investigator Clinically significant abnormality laboratory test result Confirmed rest pulse rate great 90 less 40 beat per minute ( bpm ) screening Confirmed systolic blood pressure ( SBP ) great 140 less 90 mm Hg , diastolic blood pressure ( DBP ) great 90 less 50 mm Hg screen Any major illness within 4 week prior dose acute disease state within 7 day study start Any confirm allergic reaction drug multiple allergy Any suspicion history alcohol abuse and/or consumption drug abuse Infection hepatitis B , hepatitis C virus , HIV 1 HIV 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>